Chris L. Hardesty

Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the companys neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.

LEO CANCER CARE WAS FOUNDED WITH TWO POWERFUL GOALS 1. Improve the quality of Radiation Therapy delivery through upright positioning 2. Improve access to Radiation Therapy through the removal of gantries Leo Cancer Care was founded with more than 100 years of Radiation Therapy experience by a team dedicated to challenging the norms in everything we do. Patient’s lives influence us to find a better way, a better way to improve patient care and how a patient experiences it. A better way to increase the accessibility of cancer treatments for more patients in more places. We believe our technology is that better way. Our family of world class products can provide a streamlined and efficient treatment while making the patient feel in control and hopeful. Originally founded in Australia, Leo Cancer Care has been built on research from across the globe showing the clinical benefits of upright patient positioning. Combining this with a shift from machine rotation to patient rotation, Leo Cancer Care is set to change the face of Radiation Therapy for good. *Please note that Leo Cancer Care products are not yet commercially available as we work towards FDA approval and CE mark.

Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the companys neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.

Remidio is an innovative ISO 13485 certified medical device company that seeks to create Healthcare Access by combining the simplicity of product design with cutting edge technology and sustainable business model innovations. Remidio uses principles of Design Thinking and involves key stakeholders during the product development process – clinicians, patients, and health workers, with a view to designing product solutions that are simple to use, clinically relevant, reliable, and scalable. Remidio’s CE marked and FDA 510k registered retinal imaging devices have helped screen and impact more than 7.5 million patients in 15 countries globally, as a result of increased access provided by the ease of use and affordability of Remidio’s patented optics on the smartphone platform.

VentureBlick is the trusted Go Global partner for healthcare innovation. We connect key players worldwide to foster impactful collaborations, helping startups scale, SMEs with global expansion, and corporations in discovering new technologies on a global scale. Headquartered in Singapore, VentureBlick operates across major markets including Korea, India, and China. We offer tailored insights and on-the-ground support, powered by our local teams and a curated network of over 6,500 clinicians and domain experts across 30+ specialties in 60+ countries. We leverage our healthcare community and proprietary platform, VB Discovery, which serves as the “eyes and ears” of emerging healthcare innovations. VB Discovery maximises reach and efficiency, ensuring our clients stay at the forefront of industry trends. With a proven track record, we support a diverse portfolio of clients — from startups to large corporations — in achieving global growth. Our services span global expert insights, go-to-market strategies, open innovation and technology scouting, acceleration programmes, and healthcare partnerships. Visit www.ventureblick.com to learn more. Let the venture begin!

Pureland Global Venture (“Pureland”) is a global healthcare venture capital firm. As Enterprise Singapore’s designated co-investment partner, our mission is to deliver medical solutions and savings to over 100 million people around the world. At Pureland, we look for visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. Focused on early to growth-stage investments, Pureland specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. We have particular interests in areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic disease management. Our globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU. Our engagement extends beyond financial investment. We provide robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. We strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector.

LEO CANCER CARE WAS FOUNDED WITH TWO POWERFUL GOALS 1. Improve the quality of Radiation Therapy delivery through upright positioning 2. Improve access to Radiation Therapy through the removal of gantries Leo Cancer Care was founded with more than 100 years of Radiation Therapy experience by a team dedicated to challenging the norms in everything we do. Patient’s lives influence us to find a better way, a better way to improve patient care and how a patient experiences it. A better way to increase the accessibility of cancer treatments for more patients in more places. We believe our technology is that better way. Our family of world class products can provide a streamlined and efficient treatment while making the patient feel in control and hopeful. Originally founded in Australia, Leo Cancer Care has been built on research from across the globe showing the clinical benefits of upright patient positioning. Combining this with a shift from machine rotation to patient rotation, Leo Cancer Care is set to change the face of Radiation Therapy for good. *Please note that Leo Cancer Care products are not yet commercially available as we work towards FDA approval and CE mark.